Objective: The 'Detroit Cardiogenic Shock Initiative' is a single-arm, multicenter study to assess the feasibility of early mechanical circulatory support (MCS) in patients who present with acute myocardial infarction complicated by cardiogenic shock (AMICS) who undergo percutaneous coronary intervention.
| I N TR ODU C TI ON
Mechanical reperfusion has been performed in acute myocardial infarction complicated by cardiogenic shock (AMICS) since the mid 1980's [1] . The pivotal SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) trial cemented mechanical reperfusion as the mainstay therapy for AMICS [2] . Both American and European guidelines have thus given mechanical reperfusion a Class 1B indication [3] . Unfortunately, over the past 20 years, little progress has been made on improving survival with subsequent therapies [4, 5] . The lack of progress is particularly worrisome as the incidence of AMICS appears to be increasing. Recent CMS data indicates that AMICS increased by 53% between 2010 and 2014 [6] .
The recent Food and Drug Administration approval for the use of Impella (Abiomed, Danvers MA), a transcatheter micro-axial flow mechanical circulatory support (MCS) device, in AMICS provides a powerful new tool in the treatment of these patients. Impella is percutaneously delivered with the ability to provide 2.5 to 4.0 liters/minute of forward flow to support vital organs. In addition, the device has been shown to decrease left ventricular wall tension and increase coronary perfusion, enhancing the likelihood of left ventricular recovery [7] . with AMICS by a similar, mutually agreed-upon, best practices algorithm ( Figure 1 ). Inclusion and exclusion criteria mimicked those from the 'SHOCK' trial with an additional exclusion criteria being use of intra-aortic balloon pump counter pulsation (IABP) prior to MCS (Table 1) . AMICS comprises a heterogeneous cohort of patients ranging from pre-shock to refractory shock, therefore these inclusion and exclusion criteria were included to limit those who present in preshock as well as those with refractory shock associated with prolonged cardiac arrest. In total, complete data was available in 55 patients.
| M E TH ODS
Forty-one patients met all inclusion and no exclusion criteria and were included in the analysis (Figure 2 
| RE S U L TS
A total of 41 consecutive patients were included in this single arm, multicenter, feasibility study. Patients had an average age of 65 6 14 years, 71% were male and 59% of patients were admitted to the hospital in cardiogenic shock; baseline demographics are listed in Table 2 . Prior to receiving MCS 93% of patients were on vasopressors or inotropes, 15% had witnessed out of hospital cardiac arrest with ROSC within 30 minutes, 27% had an in-hospital cardiac arrest, and 17% were under active cardiopulmonary resuscitation while the Impella was being implanted ( Table 2 ).
Patients presented with elevated heart rates, poor hemodynamics despite continuous infusion of vasopressors and inotropes, signs of tissue hypoperfusion and end-organ dysfunction ( Table 3 ). The majority of patients presented with STEMI (88%). Patients were revascularized promptly with a median door to balloon time of 85 6 47 minutes.
Angiographic success was achieved in the vast majority, with 87% of patients achieving Thrombolysis In Myocardial Infarction (TIMI) III flow after PCI.
In accordance to the algorithm, 66% of patients had implementation of MCS prior to PCI. Right heart catheterization and hemodynamic monitoring was performed in 83% of patients. An Impella CP device was used in the majority of cases (95%). Rapid door to support times were achieved and averaged 83 6 58 minutes (Table 4) .
Inotropes and vasopressors support were reduced in 71% of patients within the first hours of MCS. Cardiac power output (CPO) was measured in 85% of patients with 40% of patients having both pre and post CPO measurements, all of whom had an increase in cardiac power ( Figure 3 ). 87% of patients had a CPO 0.6 W after discharge from the cath lab. Pre-procedure CPO was 0.57 W and post-procedure CPO was 0.95 W, representing a 67% increase in cardiac power output (p < 0.001), see Figure 3 . Four patients required escalation of MCS and were subsequently transferred for evaluation of durable left ventricular assist devices (LVAD). All four of these patients survived to native recovery without need for a durable LVAD.
BASIR ET AL.
| 455
In the above cohort 85% of patients survived until device explant and 76% survived to discharge ( Figure 4 ). Overall adherence to the protocol was satisfactory given the large number of operators participating in the care of AMICS within these 5 institutions; 66% of patients received MCS prior to PCI and 83% of patients received invasive hemodynamic monitoring in the form of right heart catheterization. 
| D I SCUSSION
Our results suggest that a regional shock protocols emphasizing rapid early delivery of MCS with invasive hemodynamics is feasible and maybe associated with improved outcomes in the care of AMICS.
These findings corroborate previous observations in the USpella and CVAD registries that MCS instituted prior to PCI is associated with improved survival. In patients managed with early MCS and PCI, we Given the small number of randomized trials with associated small sample sizes, investigators must look to other sources of data to derive meaningful outcomes to positively change survival in AMICS. We recently published the largest series of MCS use in AMICS using data from the 'global Catheter-based Ventricular Assist Device (cVAD)
Registry' [9] . We found that rapid early delivery of MCS, prior to escalating doses of inotropes, prior to PCI and with delivery of MCS within 90 minutes of shock onset; was associated with an improved survival.
Similarly, outcomes from the Impella Quality (IQ) database, which included over 15,000 patients who presented with AMICS treated with MCS, found that survival was improved when MCS was delivered prior to PCI, when hemodynamic monitoring with pulmonary arterial catheters was performed and when institutional experience with the use of MCS in AMICS was present [10] .
Using these findings the collaborators of the Detroit Cardiogenic
Shock Initiative came together with the primary aim of establishing a to assess the need for MCS escalation and to safely and rapidly wean inotropes, and [5] to improve survival to discharge in >80% of patients.
The main finding from our study is that regional shock protocols emphasizing rapid early delivery of MCS with invasive hemodynamic [10] [11] [12] .
Hemodynamic monitoring with pulmonary arterial catheters was obtained in 83% of patients (32% pre-MCS, 51% post-MCS). Performance of a right heart catheterization (RHC) is critically important in AMICS and
shown to increase survival in the IQ database. Most importantly it allows clinicians to calculate a cardiac power output, a simple but powerful tool to assess the need for escalating MCS and to assess the ability to rapidly wean off inotropes and vasopressors. CPO is a strong, independent predictor of in-hospital mortality in patients with AMICS [13, 14] . CPO was measured in 85% of patients in our cohort. PCI and MCS resulted in an average improvement of CPO from 0.57W to 0.95W ( Figure 3 ).
With rapid delivery of MCS and revascularization, 71% of patients were able to decrease the doses of inotropes and vasopressors within 24 hours. To the best of our knowledge this is the first time delivery of MCS with PCI has been shown to reduce these potentially cardiotoxic medications in patients presenting with AMICS. We have previously shown in the CVAD registry that increasing inotropic agents are associated with increased mortality [9] . There are several limitations with our study. The study population is a small group of highly selected patients similar to those studied in prior randomized control trials such as the 'SHOCK' trial. There was a deliberate attempt by the authors to study such patients in an attempt to limit patients who present with anoxic brain injury or prolonged and refractory cardiogenic shock in whom therapies are often futile. Similarly, patients treated with IABP were excluded as IABP is a far less powerful device compared to Impella with numerous prior trials showing little to no benefit. Similarly, patients treated with IABP who then go on to need a MCS device such as Impella often have extended delays prior to the initiation of MCS and often present in refractory cardiogenic shock. Patients were also treated at high volume centers for AMICS with high usage of Impella and therefore these results may not generalize to low volume centers. Lastly there was no control group for the above analysis. The authors attempted to create a historical control from data gathered in the IQ database, however limit information on survival to explant from MCS was available.
In conclusion systematic use of a shock protocol emphasizing rapid early delivery of MCS prior to revascularization and invasive hemodynamic monitoring in patients who present with AMICS is feasible and may result in improved survival. A national, multicenter, cardiogenic shock quality initiative is underway to further validate these outcomes.
